Surgery With HIPEC in Treating Patients With a High Risk of Developing Colorectal Peritoneal Carcinomatosis

Inclusion Criteria

• •Patients presenting with the following history:
• •1. Histologically-proven colorectal adenocarcinoma
• •2. Presenting at the time of resection of the primary with one of the following 5 criteria (criteria indicating a high risk of developing PC) :
• •* Minimal PC, resected at the same time as the primary
• •* Rupture of the primary tumour inside the peritoneal cavity,
• •* Intraoperative rupture of the primary tumour during surgery
• •* Histologically-proven T4 colorectal adenocarcinoma
• •Who have received standard systemic adjuvant chemotherapy (6 months of systemic chemotherapy) :
• •1. Chemotherapy with FOLFOX4, mFOLFOX6, CapeOx or Capecitabine(the current standard treatment; it can be modified in the future in the two groups, if the standard is modified)
• •2. Given on an intent-to-treat basis (it can be stopped prematurely for miscellaneous reasons)
• •Patients who do not present any sign of tumour recurrence at the end of these 6 months of chemotherapy
• •Patients with the following general characteristics:
• •1. Age between 18 and 75 years
• •2. Performance Status (ECOG) 0, 1 or 2, life expectancy \> 12 weeks
• •3. Adequate renal, and bone marrow function: a. Leukocytes \>/= 3,000/microL; b. Absolute neutrophil count \>/= 1,500/microL; c. Platelets \>/= 100,000/Ul; d. Serum creatinine \</= 1.5 mg/dL
• •4. Hepatic function: a. AST (SGOT)/ALT (SGPT) \</= 5 X institutional (Upper Limit of Normal) ULN
• •5. Operable patients
• •6. Completion of neoadjuvant systemic chemotherapy
• •Patients will be informed and a signed consent before initiating any procedure specific to the trial